Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/4/2018
SIETES contiene 92261 citas

 
 
 1 a 20 de 736 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018;175:enero. [Ref.ID 102495]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees . JAMA Intern Med 2018:2 de abril. [Ref.ID 102494]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Intern Med 2018:2 de abril. [Ref.ID 102493]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med 2018:2 de abril. [Ref.ID 102492]
9.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
11. Cita con resumen
O'Neil ME, Nugent SM, Morasco BJ, Freeman M, Low A, Kondo K, Zakher B, Elven C, Motu'apuaka M, Paynter R, Kansagara D. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Intern Med 2017;167:332-40. [Ref.ID 102023]
12. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
13. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
14. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
16.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
17.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
18. Cita con resumen
Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs 2017;36:1 de mayo. [Ref.ID 101570]
19.Tiene citas relacionadas Cita con resumen
Livingston MD, Barnett TE, Delcher C, Wagenaar AC. Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015. Am J Public Health 2017;107:1827-9. [Ref.ID 101388]
20. Cita con resumen
Anónimo. Brazil issues first license for sale of cannabis-based drug. DIA Daily 2017:1. [Ref.ID 101349]
Seleccionar todas
 
 1 a 20 de 736 siguiente >>